- Home
- TCI vs NGNE Comparison
TCI vs NGNE Comparison
Compare TCI & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCI
- NGNE
- Stock Information
- Founded
- TCI 1983
- NGNE 2003
- Country
- TCI United States
- NGNE United States
- Employees
- TCI N/A
- NGNE N/A
- Industry
- TCI Real Estate
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- TCI Finance
- NGNE Health Care
- Exchange
- TCI Nasdaq
- NGNE Nasdaq
- Market Cap
- TCI 357.8M
- NGNE 325.3M
- IPO Year
- TCI N/A
- NGNE N/A
- Fundamental
- Price
- TCI $45.85
- NGNE $17.45
- Analyst Decision
- TCI
- NGNE Strong Buy
- Analyst Count
- TCI 0
- NGNE 7
- Target Price
- TCI N/A
- NGNE $41.86
- AVG Volume (30 Days)
- TCI 1.4K
- NGNE 132.4K
- Earning Date
- TCI 11-06-2025
- NGNE 11-14-2025
- Dividend Yield
- TCI N/A
- NGNE N/A
- EPS Growth
- TCI 11.20
- NGNE N/A
- EPS
- TCI 0.76
- NGNE N/A
- Revenue
- TCI $47,730,000.00
- NGNE N/A
- Revenue This Year
- TCI N/A
- NGNE N/A
- Revenue Next Year
- TCI N/A
- NGNE N/A
- P/E Ratio
- TCI $60.00
- NGNE N/A
- Revenue Growth
- TCI N/A
- NGNE N/A
- 52 Week Low
- TCI $25.50
- NGNE $6.88
- 52 Week High
- TCI $48.00
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- TCI 51.17
- NGNE 36.84
- Support Level
- TCI $45.43
- NGNE $18.37
- Resistance Level
- TCI $46.96
- NGNE $20.72
- Average True Range (ATR)
- TCI 0.51
- NGNE 1.27
- MACD
- TCI -0.26
- NGNE -0.11
- Stochastic Oscillator
- TCI 51.40
- NGNE 0.61
About TCI Transcontinental Realty Investors Inc.
Transcontinental Realty Investors Inc is a fully integrated externally managed real estate company. It operates multifamily and commercial properties throughout the southern United States and also invests in mortgage notes receivable and in the land that is either held for appreciation or development. The company has two business segments: the acquisition, development, ownership, and management of multifamily properties which include the rental of apartments (Residential Segment) and other tenant services, including parking and storage space rental, and the acquisition, development, ownership, and management of commercial properties which are office properties(Commercial Segment). It includes the rental of office space and other tenant services, including parking and storage space rental.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.